Eli Lilly's Dual Bet: Combination Data and a New Sales Channel Must Pull in the Same Direction
Published on 11/12/2026 at 06:24 | Editorial boerse-global.de
Eli Lilly has handed investors two distinct pieces of news in the space of a few days, and the market's task now is to work out whether they reinforce each other or simply sit side by side. The first is clinical: fresh Phase 3b results showing that pairing Taltz with Zepbound sharply outperforms Taltz on its own in psoriatic arthritis. The second is commercial: a distribution deal that widens access to two of the company's key drugs. Neither, on its own, settles the growth question.
The TOGETHER-PsA trial, run over 52 weeks, found that 43.7% of patients on the Taltz-plus-Zepbound combination hit the ACR50 endpoint, against 15.7% for those taking Taltz alone. That endpoint represents at least a 50% improvement in disease activity. Lilly presented the data at ACR Convergence and simultaneously published them in Arthritis & Rheumatology. Because the study pits the combination directly against Taltz monotherapy, investors can weigh the added benefit against a concrete alternative rather than an abstract baseline.
What the Trial Does and Doesn't Prove
A clear gap between two treatment arms is a strong starting point. Turning it into revenue is a separate exercise. The economic case rests on whether the combination earns a broader role in clinical practice, and that depends on uptake rather than on the elegance of the trial design. Management has flagged no specific launch timeline for the combination; what investors do have is a medical rationale that still needs commercial validation.
That is where the second strand of news comes in. On Friday, Lilly and Hims & Hers Health agreed to make Zepbound and Foundayo available to eligible patients through the latter's platform at Lilly's self-pay prices. Entry pricing starts at $149 a month for Foundayo and $299 for Zepbound. Reuters reported the arrangement as well. The deal addresses a different lever entirely — access — and its contribution will be measured in prescriptions filled, not in statistical significance.
Should investors sell immediately? Or is it worth buying Eli Lilly?
Jefferies Raises Its Sights
Sell-side sentiment has moved in Lilly's favour. Jefferies analyst Akash Tewari lifted his price target to $1,700 from $1,610 on Monday, keeping a buy rating on the stock, according to media reports. His rationale centred on the potential of international GLP-1 markets. That call adds a geographic dimension to a thesis that might otherwise look purely domestic, though it too hinges on Lilly actually converting the opportunity into demand.
The stock has already run up 40% since the start of the year, which raises the bar for what counts as good news from here. Clinical wins must now be substantial enough to justify expectations that are already priced in.
A Safety Caveat Lands at an Awkward Moment
Not every regulatory development has been favourable. On Monday the FDA called for additional warnings on GLP-1 medicines, a group that includes Lilly's Mounjaro and Zepbound. The labels would flag a potentially elevated risk of NAION, a rare eye condition that can cause permanent vision loss. Lilly said it is reviewing the update. Because Zepbound forms part of the Taltz combination under study, the warning touches the very asset the new data are meant to promote. Should safety concerns curb acceptance or constrain use, the efficacy advantage will have to hold up within a more cautious risk-benefit calculation.
Separately, Lilly said on Monday that Foundayo met its primary endpoint after 52 weeks, reducing the severity of sleep apnoea. The company intends to file the ATTAIN-OSA results with the FDA for moderate-to-severe obstructive sleep apnoea by the end of 2026.
Two Dates to Watch
The near-term calendar offers two checkpoints. Lilly has scheduled an Innovation Day for 7 December, where investors can expect further detail on development strategy. The Foundayo filing, due by the end of 2026, is the other fixed marker. Between them, they should clarify how the company intends to convert clinical momentum into commercial traction.
The coherent bull case ties these threads together: convincing treatment results, progress on additional indications, and a distribution channel that eligible patients actually use. If the Hims & Hers route generates only limited uptake, its contribution to the business will be correspondingly modest, and the international GLP-1 opportunity will matter only to the extent that Lilly captures real demand. A weaker commercial outcome could weigh on the thesis even if the science keeps advancing. For now, the burden of proof sits on execution — on both the clinical and the commercial side at once.
Ad
Eli Lilly Stock: New Analysis - 12 November
Fresh Eli Lilly information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
